BofA Securities Downgrades Edwards Lifesciences (EW) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to BofA Securities Downgrades Edwards Lifesciences (EW) to Neutral
July 24, 2024 4:15 PM EDT
IRVINE, Calif.--(BUSINESS WIRE)--
Edwards Lifesciences (NYSE: EW) today announced investments that reflect the companys deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth.
Edwards has entered into an agreement to acquire JenaValve Technology, a pioneer in the transcatheter treatment of aortic regurgitation (AR), a deadly disease that impacts a significant and growing population and is largely untreated today. JenaValve presented positive results of its U.S. pivotal trial for the treatment of symptomatic, severe AR in... More
July 24, 2024 4:15 PM EDT
IRVINE, Calif.--(BUSINESS WIRE)--
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2024.
Highlights and Outlook
Q2 sales grew 7%; constant currency1 sales grew 8%
Q2 TAVR sales grew 5%; constant currency1 sales grew 6%
Q2 TMTT sales grew 75%; increasing contribution to Edwards' growth
Q2 EPS of $0.61; adjusted1 EPS of $0.70
Significant TAVR and TMTT clinical evidence to be presented at TCT in October 2024
Positive EVOQUE introduction with excellent patient outcomes; NCD process on...
More
